Journal: PLoS ONE

Article Title: Validity of six consumer-level activity monitors for measuring steps in patients with chronic heart failure

doi: 10.1371/journal.pone.0222569

Figure Lengend Snippet: Outcome measures of the criterion validity in the field study of healthy individuals.

Article Snippet: In one free-living study, the FC2 overestimated steps by 32.2% compared to the Actigraph [ ].

Techniques:

Journal: PLoS ONE

Article Title: Validity of six consumer-level activity monitors for measuring steps in patients with chronic heart failure

doi: 10.1371/journal.pone.0222569

Figure Lengend Snippet: Outcome measures of the criterion validity in the field study of HF patients.

Article Snippet: In one free-living study, the FC2 overestimated steps by 32.2% compared to the Actigraph [ ].

Techniques:

Journal: PLoS ONE

Article Title: Validity of six consumer-level activity monitors for measuring steps in patients with chronic heart failure

doi: 10.1371/journal.pone.0222569

Figure Lengend Snippet: (A) Withings Go; (B) Omron HJ-322U-E; (C) SmartLAB walk+; (D) Garmin vívofit; (E) Garmin vívofit 3; (F) Fitbit Charge 2. The solid lines indicate the mean step count difference between the criterion device (Actigraph) and each of the evaluated consumer-level activity monitors. The dashed lines represent limits of agreement (±1.96*SD).

Article Snippet: In one free-living study, the FC2 overestimated steps by 32.2% compared to the Actigraph [ ].

Techniques: Activity Assay

Journal: PLoS ONE

Article Title: Validity of six consumer-level activity monitors for measuring steps in patients with chronic heart failure

doi: 10.1371/journal.pone.0222569

Figure Lengend Snippet: Outcome measure of the criterion validity in the lab-based study at various treadmill speeds.

Article Snippet: In one free-living study, the FC2 overestimated steps by 32.2% compared to the Actigraph [ ].

Techniques:

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Article Title: ImmunoPET, [64Cu]Cu-DOTA-anti-CD33 PET-CT, imaging of an AML Xenograft model

doi: 10.1158/1078-0432.CCR-19-1106

Figure Lengend Snippet: The humanized anti-CD33 mAb in vitro and in vivo CD33 targeting as an ADC and RIT was explored. A) In vitro cell killing of MV4–11 cells by anti-CD33 + ADC. Significant cell killing over untreated cells was seen from 500 ng −2.5 μg of Ab. (B) AML bearing mice were treated with anti-CD33 mAb + 2° Ab (anti-Human Fc) conjugated to MMAE. Untreated mice or 2° Ab-ADC only treated mice was used as controls. The BLI intensity (photons/s) of whole mouse was calculated and plotted at day 24 days post intervention. The mice treated with the anti-CD33 + 2° Ab-ADC combination reduced disease burden significantly in comparison to ADC only treated mice (p=0.02) or untreated mice (p=0.0008) (n≥4). (C) Three different activities of humanized [225Ac]Ac-DOTA-anti-CD33 (100 nCi, 200 nCi, 300 nCi) were injected into AML bearing mice. All activities efficiently reduced leukemia burden as measured by BLI intensity (photons/s) at 14 days post intervention in comparison to levels in untreated AML-bearing mice (n=5). Statistical significance was determined using ANOVA and considered significant when p<0.05.

Article Snippet: Humanized anti-CD33 and secondary (2°) Ab-ADC in vitro and in vivo The therapeutic potential of humanized anti-CD33 mAb as an ADC was evaluated indirectly using anti-human IgG (Fc) 2° Ab conjugated to monomethyl auristatin E, (MMAE) (Moradec, LLC, San Diego, CA).

Techniques: In Vitro, In Vivo, Comparison, Injection